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Abstract
Background: We recently showed that beta-defensins have antimicrobial activity against
nontypeable Haemophilus influenzae (NTHi) and that interleukin 1 alpha (IL-1 alpha) up-regulates
the transcription of beta-defensin 2 (DEFB4 according to new nomenclature of the Human
Genome Organization) in human middle ear epithelial cells via a Src-dependent Raf-MEK1/2-ERK
signaling pathway. Based on these observations, we investigated if human middle ear epithelial cells
could release IL-1 alpha upon exposure to a lysate of NTHi and if this cytokine could have a
synergistic effect on beta-defensin 2 up-regulation by the bacterial components.
Methods: The studies described herein were carried out using epithelial cell lines as well as a
murine model of acute otitis media (OM). Human cytokine macroarray analysis was performed to
detect the released cytokines in response to NTHi exposure. Real time quantitative PCR was done
to compare the induction of IL-1 alpha or beta-defensin 2 mRNAs and to identify the signaling
pathways involved. Direct activation of the beta-defensin 2 promoter was monitored using a beta-
defensin 2 promoter-Luciferase construct. An IL-1 alpha blocking antibody was used to
demonstrate the direct involvement of this cytokine on DEFB4 induction.
Results: Middle ear epithelial cells released IL-1 alpha when stimulated by NTHi components and
this cytokine acted in an autocrine/paracrine synergistic manner with NTHi to up-regulate beta-
defensin 2. This synergistic effect of IL-1 alpha on NTHi-induced beta-defensin 2 up-regulation
appeared to be mediated by the p38 MAP kinase pathway.
Conclusion: We demonstrate that IL-1 alpha is secreted by middle ear epithelial cells upon
exposure to NTHi components and that it can synergistically act with certain of these molecules
to up-regulate beta-defensin 2 via the p38 MAP kinase pathway.
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Following the common cold, otitis media (OM), or
inflammation of the middle ear, is the most frequent ill-
ness resulting in visits to physicians and the most com-
mon cause of hearing impairment in children [1]. The
majority of the cases of OM are caused by three patho-
gens: Streptococcus pneumoniae, nontypeable Haemophilus
influenzae (NTHi) and Moraxella catarrhalis [2,3].
Bacterial adherence to mucosal surfaces is a first step in
respiratory infections. NTHi, S. pneumoniae and M.
catarrhalis have all been shown to adhere to human upper
respiratory epithelial cells [4-10]. Li and colleagues dem-
onstrated that NTHi binds to and activates toll-like recep-
tor 2 (TLR2) on the surface of epithelial cells [11]. The
TLRs have been shown to be involved in the activation of
many host genes, including cytokines, chemokines and
antimicrobial peptides such as β-defensin 2 [12-14].
The defensins are cationic (polar) molecules with spatially
separated hydrophobic and charged regions. In vitro, the
defensins (at micromolar concentrations) have a broad
spectrum of antimicrobial activity against bacteria, fungi,
and even some enveloped viruses [15,16]. In humans and
other vertebrates, the defensins can be divided into the α-
and β-defensin subfamilies on the basis of the position
and bonding of six conserved cysteine residues. The α-
defensins are produced by neutrophils and intestinal
Paneth's cells [17]. The β-defensins, on the other hand, are
mainly produced by epithelial cells of the skin, kidneys,
and trachea-bronchial lining of nearly all vertebrates [18-
20]. Multiple β-defensin genes have been identified and
three have been characterized at the peptide level [21-23].
β-defensin 1 is expressed constitutively by variety of cell
types, while β-defensin 2 expression is highly up-regu-
lated by exposure to inflammatory stimuli such as bacte-
rial components or proinflammatory cytokines [24,25].
We have recently shown that both human β-defensin 1
and 2 have bactericidal /bacteriostatic activity against
NTHi [26]. Moreover, in another study, we demonstrated
that IL-1α can upregulate the transcription of β-defensin 2
in human middle ear epithelial cells, mediated by a Src-
dependent Raf-MEK1/2-ERK signaling pathway [27]. In
accord with our observations, IL-1α has also shown to be
a potent activator of β-defensin 2 in intestinal epithelial
cells [28]. Furthermore, the biological relevance of IL-1α
as an inducer of β-defensin 2 in the tubotympanum has
been demonstrated in in vivo studies that have shown IL-
1α to be one of the cytokines induced in a rat model of
OM [29].
In the present study we demonstrate that NTHi treatment
of human middle ear epithelial cells results in release of
IL-1α and that this cytokine and NTHi can synergistically
up-regulate human β-defensin 2 (DEFB4) expression.
Here, a note should be added regarding the new nomen-
clature of the b-defensin family of molecules
http:www.gene.ucl.ac.uk/cgi-bin/nomenclature/search
genes.pl. Human b-defensin 2 is now called DEFB4 and its
mouse orthologue is called b-defensin 4 (Defb4). This
change has created some confusion in the scientific com-
munity. Thus, to avoid confusion and remain consistent
with the nomenclature used in our previous studies, will
continue to refer to molecule under investigation as b-
defensin 2.
Methods
Reagents
Recombinant interferon-γ-inducible protein-10 (IP-10),
regulated upon activation, normally T-expressed, and pre-
sumably secreted (RANTES), interleukin (IL)-1α, IL-6, IL-
8 and macrophage inflammatory protein-1β (MIP-1β)
were purchased from Sigma (St. Louis, MO). PD98059
(ERK MAP kinase inhibitor), SB203580 (p38 MAP kinase
inhibitor), and SP600125 (Jun N-terminal kinase inhibi-
tor) were purchased from Calbiochem (San Diego, CA).
Preparation of bacterial lysate
NTHi strain 12, originally a clinical isolate from the mid-
dle ear fluid of a child with acute otitis media, was used in
this study [30]. A single colony of NTHi was harvested
from a chocolate agar plate, inoculated into 30 ml of brain
heart infusion broth supplemented with nicotinamide
adenine dinucleotide (3.5 µg/ml) and placed in a shaking
incubator overnight. The supernatant was discarded after
centrifugation at 10,000 × g for 10 minutes. The pellet was
resuspended in 10 ml of phosphate-buffered solution
(PBS) and sonicated to lyse the bacteria. The lysate was
then centrifuged at 10,000 × g for 10 min and the super-
natant was collected. The protein concentration of the
NTHi lysate was determined using the Bicinchoninic
(BCA) protein assay and was in the range of 0.15 mg/ml.
Cell culture
The human middle ear epithelial cell line (HMEEC),
immortalized with the E6/E7 genes of human papilloma
virus type 16 [31], was maintained in a 1:1 mixture of
Dulbecco's modified Eagle's medium (DMEM) (Invitro-
gen, Carlsbad, CA) and bronchial epithelial basal
medium (Clonetics, Walkersville, MD) supplemented
with bovine pituitary extract (52 µg/ml), hydrocortisone
(0.5 µg/ml), hEGF (0.5 ng/ml), epinephrine 0.5 (mg/ml),
transferrin (10 µg/ml), insulin (5 µg/ml), triiodothyro-
nine (6.5 ng/ml), retinoic acid (0.1 ng/ml), gentamycin
(50 µg/ml), and amphotericin-B (50 ng/ml). Hela
(human cervix epithelial) cells and A549 (human lung
epithelial) cells were purchased from the ATCC (Manas-
sas, VA), and maintained in DMEM containing 10% fetal
bovine serum (Invitrogen), penicillin (100 units/ml), andPage 2 of 10
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and IL-1α, the cells were seeded into six-well plates in trip-
licate, and were pretreated for one hour with or without
chemical inhibitors of MAP kinase including PD98059,
SB203580, and SP600125. All cells were maintained in a
humidified atmosphere of 5% CO2 and 95% air.
Animal studies
Eighteen, 10 week-old male C57BL/6 mice were used in
this study. Three mice were for each time point including
two control groups: non-treated and PBS-inoculated.
All aspects of animal handling were performed according
to approved IACUC guidelines. The mice were transtym-
panically inoculated with 10 µl of the NTHi lysate (1:10
dilution) after anesthesia with Ketamine (5 mg/100 g).
Middle ear mucosal RNA was then harvested at 6, 9, 12
and 24 hours post inoculation by irrigation of the bulla
with three, 3.5 µl Trizol washes (Invitrogen). Briefly, the
mice were anesthetized using Ketamine (5 mg/100 g), and
then decapitated. A small incision (1 cm) was made in the
retroauricular area and the cortical bone of the bulla was
exposed after dissection. A hole, sized 2 mm × 2 mm, was
made using the sharp scalpel followed by irrigation of the
bulla with Trizol. The total Trizol volume was then
increased to 200 µl and RNA was precipitated per the
manufacturer's instructions. The middle ear mucosa was
inflamed in all NTHi-treated mice, but effusion was not
seen in all groups. No sepsis or death occurred as a result
of the experimental treatment.
Protein assay
A solid phase multiplexed protein assay in a sandwich
ELISA format was performed to detect various cytokines
simultaneously. Briefly, HMEEC medium was harvested
48 hours after treatment with NTHi or PBS. Pre-blotted
membranes with various anti-cytokine antibodies in the
BioSource Human Cytokine Set 1 Cartesian Array™ (Bio-
Source, Camarillo, CA) were incubated with culture
medium for 2 hours at room temperature after blocking
nonspecific binding sites per the manufacturer's instruc-
tions. After adding a biotin-conjugated anti-cytokine anti-
body mixture (provided in the kit), the membrane was
incubated with HRP-conjugated streptavidin per the man-
ufacturer's instructions. Signal intensity was quantified by
densitometry.
Quantitation of IL-1α
Released IL-1α was measured using Human IL-1α ELISA
Kit (Endogen) according to the manufacturer's instruc-
tions. Briefly, HMEEC medium was added into anti-
human IL-1α precoated 96-well plates and incubated for
one hour at room temperature. After adding biotinylated
anti-cytokine antibody (provided in the kit), the 96-well
plate was incubated with streptavidin-HRP solution for 30
minutes. Color was developed with TMB substrate solu-
tion after washing and the absorbance was measured at
450 nm minus 550 nm. The amount of IL-1α in unknown
samples was determined after calculating the standard
curve of reconstituted IL-1α diluents.
Reverse transcription and real time quantitative PCR
Total RNA was extracted using the RNeasy kit (Qiagen,
Valencia, Ca) and cDNA was synthesized using the Taq-
Man reverse transcription kit (Applied Biosystems, Foster
City, CA). Taqman primers and probes for β-defensin 2
(DEFB4) (ABI assay number Hs00823638_m1
(NM_004942)), IL-1α (ABI assay number
Hs00899844_m1 (NM_000575)) and cyclophilin D (ABI
assay number Hs00234593_m1 (NM_005038)) were
purchased from Applied Biosystems. Multiplex PCR was
performed using 7500 Real Time PCR System (Applied
Biosystems) and cycle threshold (CT) values were ana-
lyzed. CT values of DEFB4 or IL-1α were normalized with
the internal control, and results were expressed as a fold-
induction of mRNA quantity, taking the value of the non-
treated group as 1.
Promoter construct of DEFB4
Reporter construct of β-defensin 2 promoter (p2.7hBD2-
luc) was generated as described [27]. Briefly, 5' flanking
region (from -2625 to + 1) of β-defensin 2 (DEFB4)
(AF_071216) was isolated by PCR amplification with the
following primers: 5'-GAG GTA CCT CCA TCC TTT ACT
GTG ATG ATG CC-3' (forward primer with Kpn1 tail), 5'-
GAA AGC TTT GGC TGA TGG CTG GGA GCT TCA CCA
(reverse primer with HindIII tail). The amplified product
was subcloned into the multiple cloning site of the pGL3-
Basic luciferase reporter plasmid (Promega, Madison,
WI). The reporter construct was sequenced to verify
number and orientation of inserted oligonucleotides.
Transfection and Luciferase assay
All transient transfections were carried out in triplicate
using TransIT-LT1 (Panvera, Madison, WI) according to
the manufacturer's instructions. Cells were seeded into
six-well plates at a density of 1.5 × 105 cell/well, and were
transfected with p2.7hBD2-luc plasmid upon reaching
60% confluence. The transfected cells were not selected
with antibiotics. NTHi lysate or IL-1α was added to the
transfected cells 40 hrs post transfection. Cells were har-
vested after 8 hrs, and luciferase activity was measured
using a luminometer (Pharmingen, La Jolla, CA) after
mixing with luciferase substrate (Promega), per the man-
ufacturer's instructions. The results were expressed as fold
increase of luciferase activity, compared to non-treated
controls.Page 3 of 10
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Cell culture medium was collected 48 hrs after treatment
with NTHi lysate. The medium was briefly centrifuged to
remove the cellular debris and diluted 1:4. The diluted
medium was then incubated with an anti-interleukin 1α
antibody (20, 40 and 80 µg/ml) (Endogen, Woburn, MA)
or with non-immunized rabbit IgG (20 µg/ml) (Sigma)
for 30 min at room temperature. The antibody treated
medium was then used to replace the medium on HMEEC
transfected with the DEFB4 promoter construct. Cells
were harvested after 8 hrs, and luciferase activity was
measured as described above.
Statistics
All experiments were carried out in triplicate. Results are
expressed as mean ± standard deviation. Statistical analy-
sis was performed using Student's t-test, with significance
considered to be p < 0.01 or p < 0.05.
Results
Release of cytokines by NTHi lysate treatment in the 
middle ear epithelial cells and their effect on β-defensin 2 
expression
Culture medium from human middle ear epithelial cells
was collected 48 hours after NTHi lysate treatment and the
release of cytokines was analyzed using a membrane blot-
ted with various anti-cytokine and chemokine antibodies.
IL-1α, MIP-1β, IL-6, IP-10, IL-8 and RANTES were present
at significantly higher levels after stimulation with NTHi
lysate (Figure 1A). Additionally, NTHi lysate treatment
resulted in the secretion of IL-1α, but not IL-1β (data not
shown). In order to test the effect of the cytokines on β-
defensin 2 mRNA levels, human middle ear epithelial
cells, Hela and A549 cells were treated with IL-1α, MIP-1β,
IL-6, IP-10, IL-8 and RANTES. As shown in Figure 1B, only
IL-1α treatment resulted in an up-regulation of β-defensin
2 (DEFB4) mRNA in HMEEC and A549 cells, but not in
Hela cells.
Upregulation of IL-1α by NTHi treatment in the middle 
ear epithelial cells
Levels of secreted IL-1α were quantified by ELISA, and
were at 46.0 ± 6.1 pg/ml/106 cells and 76.8 ± 13.9 pg/ml/
106 cells (mean ± standard deviation) after 24 and 48
hours, respectively (Figure 2A). No IL-1 protein was
detectable in media from the control cells or after 4 hours.
To study the time course of the induction of IL-1α mRNA
by NTHi components, Hela, A549 and HMEEC cells were
treated with the bacterial lysate and RNA was extracted
from the cells at different times. As shown in Figure 2B,
treatment of the cells with NTHi lysate up-regulated IL-1α
expression in a time dependent manner in Hela, A549
and HMEEC cells. To study the effect in animals, NTHi
lysate was inoculated into the mouse middle ear. The mid-
dle ear mucosa was inflamed in all NTHi-treated mice, but
effusion was not noted in all cases. As shown in Figure 2C,
(A) Human cytokine macroarray analysis shows NTHi-induced release of cytokines by middle ear epithelial cellsFigure 1
(A) Human cytokine macroarray analysis shows NTHi-induced release of cytokines by middle ear epithelial cells. Cell culture 
medium was harvested at 48 hrs after NTHi lysate treatment and the released cytokines were detected using asolid phase mul-
tiplexed protein assay in a sandwich ELISA format. Cells were treated with NTHi lysate (NTHi) or vehicle (No Tx). (B) Real 
time quantitative PCR analysis shows regulation of β-defensin 2 (DEFB4) mRNA by cytokines and chemokines. Only IL-1α 
treatment results in an up-regulation of β-defensin 2 (DEFB4) mRNA in HMEEC and A549 cells, but not in Hela cells.Page 4 of 10
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the up-regulation of IL-1α mRNA in the mouse model.
Synergistic effect of IL-1α on NTHi-induced β-defensin 2 
upregulation
To test if NTHi components and IL-1α could synergisti-
cally activate β-defensin 2 transcription, the human β-
defensin 2 (DEFB4) promoter construct was transfected
into HMEEC followed by treatment with NTHi lysate and
IL-1α, separately or together. As shown in Figure 3, treat-
ment of HMEEC with NTHi lysate (Figure 3A) or IL-1α
(Figure 3B) separately resulted in an up-regulation of the
β-defensin 2 promoter activity in a dose dependent man-
ner. Interestingly, NTHi treatment of HMEEC resulted in
the up-regulation of β-defensin 2 while Hela and A549
cells poorly responded (Figure 3C). Co-treatment of
HMEEC cells with suboptimal doses IL-1α and NTHi
lysate, however, had a synergistic effect on the activation
of the β-defensin 2 mRNA (Figure 3D) and its promoter
(Figure 3E). In contrast, this synergistic effect was not
noted in Hela or A549 cells (Figure 3D). Moreover, the
synergistic effect in HMEEC cells was inhibited by the p38
inhibitor (SB203580), but not by the MEK inhibitor
(PD98059) (Figure 4). These results suggest that unlike IL-
1α, which up-regulates β-defensin 2 transcription via the
ERK pathway, the synergistic up-regulation of β-defensin
2 transcription by IL-1α and NTHi components is medi-
ated via the p38 MAP kinase pathway.
(A) HMEEC releases IL-1α by treatment with NTHi lysateFigure 2
(A) HMEEC releases IL-1α by treatment with NTHi lysate. Cell culture medium was collected at 4, 24 and 48 hrs after treat-
ment. Released IL-1α was quantified using ELISA (ND – not detectable). Treatment with NTHi lysate up-regulates IL-1α 
expression in a time dependent manner in Hela, A549 and HMEEC cells (B). Cells were treated with NTHi lysate for 2, 4 and 
8 hours, and real time quantitative PCR was performed after RNA purification and reverse transcription. Inoculation of NTHi 
lysate into the middle ear results in the up-regulation of IL-1α mRNA in the mouse model (C). Mice were transtympanically 
inoculated with NTHi lysate and mucosal RNA was extracted after 6, 9, 12 and 24. Control animals received PBS. The RNA 
samples were reverse transcribed and analyzed by real time quantitative PCR. Values are given as mean ± standard deviation. N 
= 3. *: p < 0.05, **: p < 0.01.Page 5 of 10
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Individual and synergistic regulation of β-defensin 2 (DEFB4) by NTHi lysate and IL-1αFigure 3
Individual and synergistic regulation of β-defensin 2 (DEFB4) by NTHi lysate and IL-1α. Luciferase assay of β-defensin 2 
(DEFB4) promoter activity shows dose-dependent effect of NTHi lysate (A) and IL-1α(B) in HMEEC cells. Real time quantita-
tive PCR (C) shows that HMEEC cells respond to NTHi treatment and up-regulate β-defensin 2 while Hela and A549 cells 
respond poorly. Insect: standard deviations (SD). Co-treatment of the cells with suboptimal doses IL-1α and NTHi lysate dem-
onstrates a synergistic effect on the activation of the β-defensin 2 mRNA in HMEEC cells. The synergistic effect was not noted 
in Hela or A549 cells (D). Luciferase assay of HMEEC cells (E) shows synergistic transcriptional regulation by NTHi lysate 
(1:100 dilution) and IL-1α (50 pg/ml) co-treatment. Values are given as the mean ± standard deviation. N = 3. *: p < 0.05, **: p 
< 0.01.
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2 inducing factor
In order to prove that IL-1α was the cytokine responsible
for the transcriptional activation of the β-defensin 2 pro-
moter, HMEEC culture medium was collected 48 hrs after
treatment of the cells with the NTHi lysate, diluted 1:4
with fresh media and treated with an IL-1α neutralizing
antibody, or with pre-immune IgG. The antibody treated
medium was next added to human middle ear epithelial
cells transfected with the β-defesnisn 2 promoter con-
struct. As shown in Figure 5, the activity of the β-defensin
2 (DEFB4) promoter was up-regulated by conditioned
medium from NTHi-treated cells. Moreover, the observed
induction could be blocked with anti IL-1α antibody, sug-
gesting a major role for this cytokine in the up-regulation
of β-defensin 2.
Our results suggest that middle ear epithelial cells release
IL-1α when stimulated by NTHi components, and that
this cytokine acts in an autocrine/paracrine manner to
synergistically up-regulate β-defensin 2 transcription. Fur-
thermore, in contrast to IL-1α's effect on β-defensin 2
transcription, which is mediated via the ERK MAP kinase
pathway, the synergistic effect of this cytokine on β-
defensin 2 transcription by NTHi components appears to
be mediated by the p38 MAP kinase pathway (Figure 6).
Discussion
Our results suggest that middle ear epithelial cells release
IL-1α when stimulated by NTHi components and that this
cytokine acts in an autocrine/paracrine synergistic manner
with NTHi to up-regulate β-defensin 2. Furthermore, in
contrast to IL-1α that acts via the ERK MAP kinase path-
way to induce β-defensin 2 transcription, the synergistic
effect of this cytokine on β-defensin 2 up-regulation by
NTHi molecules appears to be mediated by the p38 MAP
kinase pathway (Figure 6). Such synergism may be a way
of boosting the epithelial cells' initial response to NTHi
and its components.
The signaling mechanisms appear to be more complicated
in the presence of both exogenous and endogenous
inducers. NTHi, an exogenous inducer and TNF-α, an
endogenous inducer synergize with each other to induce
NF-κB activation and consequently up-regulate inflam-
matory mediators including IL-1β and IL-8 as well as TNF-
α [32]. NTHi first interacts with its receptors of host cells
such as Toll-like receptor 2 (TLR2) [14], and leads to the
activation of multiple signaling cascades resulting in the
up-regulation of inflammatory cytokines such as TNF-α.
The up-regulated TNF-α in response to NTHi synergize
with NTHi to induce NF-κB via two distinct signaling
pathways, the NIK-IKK-IκBα and the MEKK1-MKK3/6-
p38 MAPK pathways [32].
Strains of NTHi, a small gram-negative bacterium, exist as
commensal organisms in the human nasopharynx [33].
Nasopharyngeal colonization of NTHi may persist for
prolonged periods of time, even in the antibody-contain-
ing mucosal secretions since the bacteria undergo anti-
genic variation. This can occur by several molecular
mechanisms such as point mutation, gene amplification,
phase variation or horizontal gene transfer and homolo-
gous recombination [34]. Although NTHi rarely causes
life-threatening infections, it is nonetheless a clinically
important pathogen since it causes otitis media in chil-
dren and exacerbates chronic obstructive pulmonary dis-
ease in adults [35,36]. The interactions between NTHi and
the host are not well understood. These interactions deter-
mine chronic colonization with or without inflammation
or disease. The interaction of NTHi antigens and specific
host molecules are likely to be involved in the transition
of NTHi from a commensal to a pathogenic organism.
Further studies are, however, needed to elucidate these
mechanisms.
Our results showed that the induction of β-defenin 2 by
NTHi is not a pan-epithelial response, in that Hela and
A549 cells do not highly respond to NTHi lysates, whereas
HMEEC cells do. In addition, although NTHi treatment
up-regulated IL-1α expression in Hela, A549 and HMEEC
cells, treatment of the cells with IL-1α resulted in the up-
regulation of β-defensin 2 only in A549 and HMEEC, but
not in Hela cells. These results indicate that expression
patterns of receptors or signaling molecules is cell-specific
and thus determines the responses to extracellular stimuli.
Regulation of the synergistic activity via the p38 MAP kinase pathwayFig re 4
Regulation of the synergistic activity via the p38 MAP kinase 
pathway. Real time quantitative PCR shows that SB203580 
(10 and 20 uM) blocks the synergistic effect of IL-1α and 
NTHi lysate, but PD98059 (10 and 20 uM) does not. Values 
are given as the mean ± standard deviation. N = 3. *: p < 
0.05, **: p < 0.01. DMSO: dimethylsulfoxide.Page 7 of 10
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hypo-responsiveness of A549 cells to lipopolysaccharide
(LPS), and of A549 and normal human bronchial epithe-
lial cells to Gram-positive group B Streptococci [37,38]. A
deficiency in the expression of TLR2 and 4 may also
explain the lack response of these cells to NTHi as well.
Our experimental observation of the non-responsiveness
of Hela cells to NTHi, is on the other hand different from
previous observations demonstrating transcriptional up-
regulation of β-defensin-2 by LPS [39] or activation of NF-
κB by NTHi [14]. This apparent difference, however may
be explained by Mineshiba and colleagues' use of LPS and
the fact that Shuto and coworkers studied the nuclear
translocation of NF-κB, which may not be in itself suffi-
cient for the transcriptional activation of β-defensin-2 in
Hela cells.
Although the autolysis of NTHi has not been docu-
mented, it is likely that NTHi undergoes autolysis similar
to that seen with Haemophilus influenzae type b [40], S.
pneumoniae [41] or E. coli [42]. Cytoplasmic, as well as
membrane components of NTHi are thought to persist in
the effusion and act as long lasting inducers of inflamma-
tion. This notion is supported by the fact that bacterial
DNA is detectable in most sterile effusions [43], whereas
endotoxin is detectable in 60% of the cases [44]. While
the molecules (possibly surface antigens) of intact NTHi
have been demonstrated to induce proinflammatory
cytokines in human respiratory epithelial cells [45], other
studies have shown that the cytoplasmic fraction of lysed
NTHi also contains important molecules for stimulating
epithelial cells [46,47]. The NTHi lysate used in this study
was prepared by sonification of the bacteria and mimics
normal pathophysiology.
Interleukin 1 is a central mediator of the inflammatory
response and occurs in two forms. Although the acidic
form, known as IL-1α, and the neutral form, IL-1β, only
share 45% homology at the nucleic acid level, both pro-
teins bind to the same receptor [48,49]. Furthermore,
both proteins are pleiotropic and affect processes such as
inflammation, immunity and hemopoiesis. Moreover,
while IL-1β is active only in its secreted form, IL-1α is
active as an intracellular precursor, a membrane-associ-
ated cytokine, as well as a secreted molecule.
Our results suggest a role for IL-1α but not IL-1β in the up-
regulation of β-defensin 2 transcription. These results are
consistent with the observations that IL-1α and not IL-1β,
released from epithelial cells infected with respiratory syn-
cytial virus, enhanced expression of intercellular adhesion
molecule-1 in pulmonary epithelial cells [50]. Moreover,
our data suggest that the induction of IL-1α production in
middle ear epithelial cells and the autocrine/paracrine
effect of this molecule may be one of the central events
involved in the up-regulation of chemotactic factors for
the recruitment of immune cells into the middle ear. It
should be noted that although the concentration of IL-1α
released into the culture medium was less than 100 pg/
ml/106 cells, since the molecule is acting in an autocrine
manner, its effective concentration is likely to be much
higher locally.
Schematic illustration showing pathways involved in the indi-vidual nd syne gistic effects of IL-1α and NTHi on β-defensin 2 (DEFB4) trans ription in the midd e ear epithelial c llsFigure 6
Schematic illustration showing pathways involved in the indi-
vidual and synergistic effects of IL-1α and NTHi on β-
defensin 2 (DEFB4) transcription in the middle ear epithelial 
cells.
IL-1α is the protein secreted by NTHi-treated HMEEC cells that is responsibl  for th  transcriptional activation of th  β-defen in 2 (DEFB4) promoterFigure 5
IL-1α is the protein secreted by NTHi-treated HMEEC cells 
that is responsible for the transcriptional activation of the β-
defensin 2 (DEFB4) promoter. Treated medium – 1:4 dilution 
of the conditioned medium from cells treated with NTHi 
lysate for 48 hours. Control medium (Con-M) – 1:4 dilution 
of conditioned medium from non-treated cells. Anti-IL-1α 
antibody (20, 40 and 80 µg/ml), but not pre-immune IgG, can 
block the transcriptional activation of the β-defensin 2 pro-
moter in a dose dependent manner. Values are given as the 
mean ± standard deviation. N = 3. *: p < 0.05, **: p < 0.01.Page 8 of 10
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BMC Infectious Diseases 2006, 6:12 http://www.biomedcentral.com/1471-2334/6/12In our previous studies, we demonstrated that IL-1α could
up-regulate β-defensin 2 transcription via a Src-dependent
MEK1/2-ERK1/2 signaling pathway [27]. Interestingly
however, the present study shows that the p38 MAP
kinase, not the ERK1/2 pathway is involved in synergism
of IL-1α and NTHi components. Moreover, our prelimi-
nary results suggest that the p38 MAP kinase pathway is
involved in the activation of β-defensin 2 transcription by
NTHi (unpublished data). We postulate that the activa-
tion of ERK and p38 MAP kinase pathways can result in a
synergistic up-regulation of β-defensin 2. These results
point to the complexity of the signaling pathways that
control the expression of innate immune molecules such
as β-defensin 2 and indicate the need for further investiga-
tion into the regulation of β-defensin 2 by NTHi and IL-
1α.
Conclusion
We demonstrate that epithelial cell-derived IL-1α can syn-
ergistically act with NTHi components to up-regulate
human β-defensin 2 (DEFB4) via the p38 MAP kinase
pathway.
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